Stockreport

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF - Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving =75% improve [Read more]